Q4 EPS Estimate for ACADIA Pharmaceuticals Raised by Analyst

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Leerink Partnrs lifted their Q4 2024 earnings per share estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will earn $0.12 per share for the quarter, up from their prior forecast of $0.10. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.75 EPS, FY2027 earnings at $1.44 EPS and FY2028 earnings at $2.13 EPS.

A number of other research analysts have also recently weighed in on ACAD. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Raymond James reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.25.

ACADIA Pharmaceuticals Trading Up 1.7 %

Shares of ACAD opened at $18.69 on Thursday. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $26.83. The stock has a market cap of $3.11 billion, a P/E ratio of 23.96 and a beta of 0.37. The company has a 50-day moving average of $17.45 and a two-hundred day moving average of $16.64.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business had revenue of $250.40 million during the quarter, compared to analysts’ expectations of $248.83 million. During the same quarter last year, the business posted ($0.40) earnings per share. The business’s revenue for the quarter was up 18.3% on a year-over-year basis.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp raised its stake in shares of ACADIA Pharmaceuticals by 3.0% during the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock valued at $91,878,000 after purchasing an additional 173,084 shares during the period. Fred Alger Management LLC increased its stake in ACADIA Pharmaceuticals by 17.8% during the 3rd quarter. Fred Alger Management LLC now owns 3,186,389 shares of the biopharmaceutical company’s stock worth $49,007,000 after buying an additional 481,950 shares during the period. Geode Capital Management LLC boosted its position in ACADIA Pharmaceuticals by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company’s stock valued at $44,234,000 after buying an additional 30,826 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after acquiring an additional 1,966,607 shares in the last quarter. Finally, Rockefeller Capital Management L.P. increased its position in shares of ACADIA Pharmaceuticals by 19.5% during the third quarter. Rockefeller Capital Management L.P. now owns 1,139,934 shares of the biopharmaceutical company’s stock worth $17,532,000 after acquiring an additional 185,684 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 10,259 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $172,453.79. Following the transaction, the chief financial officer now directly owns 53,302 shares of the company’s stock, valued at $896,006.62. This trade represents a 16.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider James Kihara sold 4,073 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the completion of the sale, the insider now directly owns 19,863 shares of the company’s stock, valued at $333,897.03. The trade was a 17.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,661 shares of company stock worth $414,551 in the last three months. 28.30% of the stock is currently owned by company insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.